Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

This study has been completed.
Janssen Alzheimer Immunotherapy (JAI) Research and Development, LLC
Information provided by (Responsible Party):
Pfizer Identifier:
First received: May 24, 2007
Last updated: February 15, 2013
Last verified: February 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2013
  Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)